As the anticipation for ASH 2023 builds, Professor Graham Jackson, consultant haematologist and Myeloma UK’s Chief Clinical and Scientific Advisor, sheds light on the top abstracts to watch, offering a curated glimpse into the forefront of myeloma research.Details
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
In these consensus guidelines the International Myeloma Society have reviewed existing literature and current guidelines to address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.
Read the guidelines and recommendations here.
In a year of exceptional contributions to myeloma care, we are excited to announce that Ysbyty Gwynedd in Bangor has been honoured with the Myeloma UK’s Clinical Service Excellence Programme award for their innovative approaches to myeloma treatment.Details
This latest update presents critical developments in myeloma treatment appraisals by NICE and the SMC.
Stay informed about the latest recommendations, appeal hearings, and upcoming assessments shaping the treatment options for patients and healthcare professionals.
New NICE guidelines on managing cancer-related spinal cord compression (SCC) have been published, with Myeloma UK actively participating in their development. The guidelines aim to improve early diagnosis and treatment of SCC to prevent neurological injury and improve prognosis.Details
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The IMWG outline updates to clinical practice guidance for the management of multiple myeloma-related renal impairment.
Read the recommendations here.
The response to the COVID-19 pandemic has put the UK Government and NHS on an emergency footing. With this substantial change to NHS services, there has been a rapid growth in published guidelines and policy to help Healthcare Professionals (HCPs) ensure patients get the right treatment and care. Here we have detailed some key sources…Details
New treatment appraisals continue to come through the Health Technology Appraisal (HTA) pipeline.
Myeloma UK is involved in seven active appraisals between the National Institute for Healthcare Excellence (NICE) and the Scottish Medicines Consortium (SMC).